胰腺癌治疗中的药物遗传学及其他分子靶点。“2010年美国临床肿瘤学会年会”亮点。美国伊利诺伊州芝加哥。2010年6月4日至8日。
Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
作者信息
Merika Eirini, Syrigos Konstantinos N, Saif Muhammad Wasif
机构信息
West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College London, London, United Kingdom.
出版信息
JOP. 2010 Jul 5;11(4):328-30.
Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management through identification of molecular targets and prognostic factors to overcome the limits of efficacious chemotherapy delivery.
在2010年6月于芝加哥举行的美国临床肿瘤学会（ASCO）年会上展示的众多摘要中，有四篇聚焦胰腺癌的有趣摘要值得在本次ASCO会后评论中进一步探讨，因为它们可能为临床医生提供见解，并给患者带来希望。这些摘要通过识别分子靶点和预后因素，指出了胰腺癌治疗的未来方向，以克服有效化疗的局限性。
Zotero 插件